4D Molecular Therapeutics (NASDAQ:FDMT) Downgraded to “Sell” Rating by Wall Street Zen

Wall Street Zen cut shares of 4D Molecular Therapeutics (NASDAQ:FDMT) from a hold rating to a sell rating in a research report released on Saturday morning.

A number of other brokerages have also issued reports on FDMT. Chardan Capital restated a “buy” rating and issued a $26.00 target price on shares of 4D Molecular Therapeutics in a research note on Thursday, March 19th. Royal Bank Of Canada raised their target price on 4D Molecular Therapeutics from $32.00 to $35.00 and gave the stock an “outperform” rating in a research note on Thursday, March 19th. The Goldman Sachs Group set a $33.00 target price on 4D Molecular Therapeutics in a research note on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Monday, April 20th. Finally, Barclays began coverage on 4D Molecular Therapeutics in a research note on Wednesday, January 28th. They issued an “overweight” rating and a $33.00 target price for the company. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, 4D Molecular Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $29.88.

4D Molecular Therapeutics Price Performance

Shares of FDMT stock opened at $10.14 on Friday. The firm has a market capitalization of $530.12 million, a price-to-earnings ratio of -3.95 and a beta of 2.77. The business has a fifty day moving average of $9.38 and a 200 day moving average of $9.49. 4D Molecular Therapeutics has a 1 year low of $3.00 and a 1 year high of $12.34.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its earnings results on Thursday, May 7th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). The firm had revenue of $3.05 million during the quarter, compared to analysts’ expectations of $2.59 million. 4D Molecular Therapeutics had a negative return on equity of 37.26% and a negative net margin of 182.34%. As a group, equities research analysts expect that 4D Molecular Therapeutics will post -3.71 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Landing Point Financial Group LLC acquired a new position in 4D Molecular Therapeutics during the fourth quarter valued at $142,000. Impact Partnership Wealth LLC lifted its position in 4D Molecular Therapeutics by 36.5% during the fourth quarter. Impact Partnership Wealth LLC now owns 15,123 shares of the company’s stock valued at $113,000 after purchasing an additional 4,045 shares during the period. Gabelli Funds LLC acquired a new position in 4D Molecular Therapeutics during the fourth quarter valued at $90,000. Truist Financial Corp acquired a new position in 4D Molecular Therapeutics during the fourth quarter valued at $188,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in 4D Molecular Therapeutics in the fourth quarter valued at $175,000. 99.27% of the stock is currently owned by institutional investors and hedge funds.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.